Quick Order

Text Size:AAA

NME1 / NDKA Antibody, Rabbit PAb, Antigen Affinity Purified

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
Human NME1 Antibody Product Information
Immunogen:Recombinant Human NME1 / NDKA protein (Catalog#11615-H07E)
Clone ID:
Ig Type:Rabbit IgG
Formulation:0.2 μm filtered solution in PBS
Preparation:Produced in rabbits immunized with purified, recombinant Human NME1 / NDKA (rh NME1 / NDKA; Catalog#11615-H07E; NP_000260.1; Ala2-Glu152). NME1 / NDKA specific IgG was purified by Human NME1 / NDKA affinity chromatography.
Human NME1 Antibody Usage Guide
Specificity:Human NME1 / NDKA

ELISA: 0.1-0.2 μg/mL

This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human NME1 / NDKA. The detection limit for Human NME1 / NDKA is < 0.039 ng/well.

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Other NME1 Antibody Products
NME1/NDKA Background

NME1, also known as Nucleoside Diphosphate Kinase A (NDK-A), or NM23-H1, belongs to the NDK family. NM23-H1 is known to have a metastasis suppressive activity in many tumor cells. Recent studies have shown that the interacting proteins with NM23-H1 which mediate the cell proliferation, may act as modulators of the metastasis suppressor activity. The interacting proteins with NM23-H1 can be classified into 3 groups. The first group of proteins can be classified as upstream kinases of NM23-H1 such as CKI and Aurora-A/STK15. The second group of proteins acts as downstream effectors for the regulation of specific gene transcriptions, GTP-binding protein functions, and signal transduction in Erk signal cascade. The third group of proteins can be classified as bi-directionally influencing binding partners of NM23-H1. As a result, the interactions with NM23-H1 and binding partners have implications in the biochemical characterization involved in metastasis and tumorigenesis. NDKA is increased in human postmortem cerebrospinal fluid (CSF), a model of global brain insult, suggesting that measurement in CSF and, more importantly, in plasma may be useful as a biomarker of stroke. Additionally, NM23-H1 significantly reduces metastasis without effects on primary tumor size and was the first discovered metastasis suppressor gene.

Human NME1/NDKA References
  • Allard L, et al. (2005) PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem. 51(11): 2043-51.
  • Steeg PS, et al. (2008) Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res. 14(16): 5006-12.
  • Kim HD, et al. (2009) Regulators affecting the metastasis suppressor activity of Nm23-H1. Mol Cell Biochem. 329(1-2): 167-73.
  • Product nameProduct name